[미국특허]
Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
A61F-015/00
A61K-009/00
A61K-031/7052
A61K-031/713
A61K-048/00
A61M-037/00
C12N-015/11
C12N-015/113
A61M-025/00
출원번호
US-0028638
(2011-02-16)
등록번호
US-8957198
(2015-02-17)
발명자
/ 주소
Kaemmerer, William F.
Kaytor, Michael D.
출원인 / 주소
Medtronic, Inc.
대리인 / 주소
Fox Rothschild LLP
인용정보
피인용 횟수 :
1인용 특허 :
55
초록▼
The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging throug
The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.
대표청구항▼
1. A medical system for treatment of Huntington's disease, comprising: a) an intracranial access device;b) a mapping means for locating a predetermined location in the brain, said predetermined location comprising at least one cell expressing huntingtin;c) a deliverable amount of a small interfering
1. A medical system for treatment of Huntington's disease, comprising: a) an intracranial access device;b) a mapping means for locating a predetermined location in the brain, said predetermined location comprising at least one cell expressing huntingtin;c) a deliverable amount of a small interfering RNA, said small interfering RNA comprising a first strand and a second strand, the first strand comprising at least 19 contiguous nucleotides encoded by the group consisting of SEQ. ID. NO: 24 or SEQ. ID. NO: 25, or a vector encoding said small interfering RNA;d) a delivery means for delivering said small interfering RNA to said location of the brain from said intracranial access device. 2. The medical system of claim 1, wherein the intracranial access device is an intracranial access port. 3. The medical system of claim 1, wherein the predetermined location in the brain is the caudate nucleus, the putamen, the corona radiate or the striatum. 4. The medical system of claim 1, wherein said delivery means is an injection from an external syringe into an intracranial access port. 5. The medical system of claim 1, wherein said delivery means in an infusion pump. 6. The medical system of claim 5, wherein said infusion pump is an electromechanical pump. 7. The medical system of claim 5, wherein said infusion pump is an osmotic pump. 8. The medical system of claim 1, wherein the vector is a viral vector. 9. The medical system of claim 8, wherein the viral vector is an adeno-associated viral vector. 10. The medical system of claim 8, wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. 11. The medical system of claim 1, wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. 12. The medical system of claim 1, wherein the mapping means is patient-specific and intra-operative. 13. The medical system of claim 1, wherein the intracranial access device comprises a catheter, and wherein the catheter comprises a marker. 14. A medical system for treatment of Huntington's disease, comprising: a) an intracranial access device;b) a mapping means for locating a predetermined location in the brain, said predetermined location comprising at least one cell expressing huntingtin;c) a deliverable amount of a small interfering RNA, said small interfering RNA comprising a first strand and a second strand, the first strand comprising at least 19 contiguous nucleotides complementary to a portion of huntingtin mRNA, or a vector encoding said small interfering RNA;d) a delivery means for delivering said small interfering RNA to said location of the brain from said intracranial access device, wherein said mapping means allows an intra-operative verification of a placement of said delivery means.
Kaemmerer, William F.; Kaytor, Michael D., Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna.
Baetge Edward E. (Barrington RI) Hammang Joseph P. (Barrington RI) Gentile Frank T. (Warwick RI) Lindner Mark D. (Bristol RI) Winn Shelley R. (Smithfield RI) Emerich Dwaine F. (Providence RI), Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules.
Noonberg Sarah B. (Berkeley CA) Hunt C. Anthony (San Francisco CA), In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides deriv.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Comben Richard H. (St. Paul MN) Grant Barry J. (Roberts WI) Serfling Michael D. (St. Louis Park MN) Cross ; Jr. Thomas E. (St. Francis MN) Stanton David J. (Anoka MN), Screening cable connector for interface to implanted lead.
Mickle Donald A. G.,CAXITX M5M 2X9 ; Li Ren-Ke,CAXITX M1V 1B4 ; Weisel Richard D.,CAXITX M4X 1S8, Transplants for myocardial scars and methods and cellular preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.